Genelux is a biotechnology business based in the US. Genelux shares (GNLX) are listed on the NASDAQ and all prices are listed in US Dollars. Genelux employs 15 staff and has a trailing 12-month revenue of around $11.1 million.
tastytrade
Finder Award
SoFi Invest
M1 Finance
| Latest market close | $29.00 |
|---|---|
| 52-week range | $5.35 - $39.27 |
| 50-day moving average | $21.19 |
| 200-day moving average | $18.85 |
| Wall St. target price | $10.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.23 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $29 from 2023-06-01
| 1 week (2023-05-26) | 20.83% |
|---|---|
| 1 month (2023-05-03) | 17.69% |
| 3 months (2023-03-03) | 57.01% |
| 6 months (2022-11-29) | N/A |
| 1 year (2022-05-30) | N/A |
|---|---|
| 2 years (2021-05-30) | N/A |
| 3 years (2020-05-30) | N/A |
| 5 years (2018-05-30) | N/A |
| Revenue TTM | $11.1 million |
|---|---|
| Gross profit TTM | $11.1 million |
| Return on assets TTM | -27.58% |
| Return on equity TTM | 0% |
| Profit margin | -47.04% |
| Book value | $-4.12 |
| Market capitalisation | $704.7 million |
TTM: trailing 12 months
We're not expecting Genelux to pay a dividend over the next 12 months.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California. .
Access remote advice, planning and portfolio management from this established financial services company.
Steps to owning and managing ET, with 24-hour and historical pricing before you buy.
Steps to owning and managing UEC, with 24-hour and historical pricing before you buy.
Steps to owning and managing GROY, with 24-hour and historical pricing before you buy.
The best trading apps come with low fees and are easy to use.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.